Oxford Nanopore Technologies plc (ONT) Earnings Call Transcript & Summary

August 19, 2026

London Stock Exchange GB Health Care Life Sciences Tools and Services earnings 96 min

Earnings Call Speaker Segments

Francis Van Parys

executive
#1

Thank you for being with us today, and welcome. Let me quickly outline the flow for this session. I'll begin with a few opening comments and lay out what we expect in the near term. After that, I'll pass things to Nick, who will walk you through the first half performance and the 2026 guidance in greater detail. Following Nick, I'll return to discuss our strategy, the priorities we have established, and the outlook over the longer term. Then I'll wrap up with the main takeaways before Nick and I open the floor to your questions. Since this is my first results presentation in the role of CEO of Oxford Nanopore, let me share how I have used the past six months. The reason I joined Oxford Nanopore is a firm belief that it has what it takes to become an extraordinary company, and what I have seen during my time here confirms that. It brings together a highly differentiated technology platform, a strong research foundation, and global reach, along with the chance to unlock considerably more value than the business delivers today. Beyond working with the leadership team on running the business, my early focus has gone to listening, learning, and setting priorities. I have devoted substantial time to customers and partners, learning where we create value today, where adoption is picking up speed, and where obstacles persist.

Francis Van Parys

executive
#2

I've dedicated time throughout the organization to grasp our R&D strengths, how manufacturing runs, the way we execute commercially, and the processes that will let us scale. I've also held conversations with investors, with governments, and with other important stakeholders. Over these past five months, we've carried out a thorough examination of the business — its markets, applications, innovation priorities, and capital allocation. I've been evaluating what evolution the organization requires to underpin the next stage of growth. That effort has strengthened my conviction in this company, while also bringing into relief where we must sharpen our focus, set clearer priorities, and execute more cleanly. I'll return to those points later. Before Nick walks you through the first half performance, I want to lay out our near-term outlook along with the longer-term ambition that sits behind the strategy. Our 2026 guidance is unchanged. We still anticipate constant currency revenue growth of 16%-20% and a gross margin of approximately 62%. That guidance does not include the $20 million upfront payment stemming from the cross-licensing agreement we announced today. Nick will cover that agreement and how it is treated financially later in the presentation. We also remain on track for adjusted EBITDA breakeven in 2027 and positive free cash flow in 2028. Importantly, that is not the finish line — it is simply one step toward our longer-term ambition of building a $1 billion+ annual revenue business and beyond.

Francis Van Parys

executive
#3

During the first half, we achieved significant movement along that route, especially regarding gross margin, cost discipline and adjusted EBITDA. Nick is going to walk you through how that performance played out in more detail in a moment. Although additional effort is plainly required, notably on top line execution, the direction toward profitability and cash generation is still intact. With that said, I will pass things to Nick so he can cover the first half performance in detail.

Nicholas Keher

executive
#4

Thanks, Francis. Good afternoon, everyone. I'm Nick Keher, CFO of Oxford Nanopore. Now to the first half financials: we brought in revenues of GBP 116.7 million, which works out to 12.3% growth at constant currency. As we laid out in the July trading update, growth in the first half came in below what we had expected. The main reason is the substantial decline in China, where revenues fell roughly 16% year-on-year, reflecting tighter export control restrictions and shifts in commercial operations in that region. The continued geopolitical situation in the Middle East also produced a revenue decline of roughly 14% in that region. Excluding China and the Middle East, group revenue growth was roughly 16% at constant currency, which is a better gauge of the underlying performance across the rest of the business. The timing of customer orders and contract wins in the Americas likewise weighed on first half growth. As we've said before, we don't expect to recover those lost revenues in H2. EMEAI posted strong growth of 23.8% at constant currency, despite the disruption in the Middle East and known headwinds within the research space. While revenue growth fell short of our expectations, we achieved a gross margin of 62.2%, in line with guidance, which is a 400 basis point improvement year-on-year.

Nicholas Keher

executive
#5

Alongside a solid gross margin, the restructuring and efficiency steps we took in FY 2025 delivered visible benefits. Adjusted operating expenses declined 7% compared with the prior year, which helped drive a 54% reduction in adjusted EBITDA loss, to GBP 22.1 million. That marks meaningful movement toward breakeven. On cash, we ended the period with GBP 234.5 million in net cash, roughly GBP 70 million lower than December 2025. That mirrors the usual working capital seasonality we have experienced in earlier years, together with certain one-off items, and we anticipate a meaningful cash improvement in H2. Looking ahead, we still expect net cash to bottom out above GBP 100 million as we move through breakeven in 2028. Now to more detail on the revenue mix. Device sales rose strongly, 32.6% higher, reflecting robust growth throughout the PromethION range, with every product line increasing during the period. P2i performed especially well, with both revenues and device placements more than doubling. We expect this sizable rise in device sales to drive additional consumable pull-through over time. Reported consumable growth came in at 2.7%. As a reminder, this combines PromethION and MinION flow cells and kits. That growth rate fell short of expectations, but we see it as largely temporary for three principal reasons.

Nicholas Keher

executive
#6

To start, during H1 2025 we had several sizable research programs that brought in meaningful consumables revenue, and those did not recur in the first half of this year. Next, PromethION flow cell volumes rose by more than 20%, though lower average selling prices partly offset that, since customers shifted into discount tiers for higher volumes. Third, we observed some anticipated normalization in the revenue mix as we transitioned to the CapEx pricing model, with customers adjusting to purchasing different volumes of consumable products now that they pay for devices outright. With devices growing strongly, the P2i especially, we think this will push consumable sales higher as those customers get their new devices up and running and start placing orders. Alongside sustained underlying growth in flow cell volumes, we are showing — and the comparison gets easier as we lap the large programs that rolled off — that we expect stronger consumable growth in the second half. At the product range level, PromethION remained the growth driver for the group, again powered by the devices and the P2i in particular. On end market demand, our revenue mix keeps shifting toward the applied markets, a gradual move toward commercially funded demand that is more stable in nature and an important part of where we plan to focus growth over time.

Nicholas Keher

executive
#7

Revenue from research rose 5.4%, reaching GBP 76 million, even with the hit from NIHR, GEL 2.0 and PRECISE II, all of which concluded last year. Taken together, those contracts created a headwind of roughly GBP 8.3 million, or 11.5%, for segment revenues. Growth was helped in particular by securing the SequenceME program in EMEAI. Clinical stood out as the fastest-expanding end market during the period, posting revenue of GBP 17.6 million, which is up 35.4% on a reported basis. The increase came from reimbursement-funded labs that run assays or work on developing new clinical methods. I'd also point to the prominent contract win with MyOme, a Natera company, that we announced today in the rare disease area, which will serve as a growth driver going forward. We keep posting robust growth throughout biopharma, where revenues hit GBP 9.5 million, a rise of 25% versus the prior year, and there's more ahead given the ongoing uptake among both R&D and QC customers. Industrial revenue posted modest growth to GBP 30.7 million, up 6.2% year-on-year, powered by steady adoption of our plasmid sequencing capabilities. Now to our gross margin bridge: we've once again achieved solid underlying margin improvement, with gross margin coming in at 62.2%, consistent with FY 2026 guidance.

Nicholas Keher

executive
#8

As we anticipated, the fact that the GBP 3.3 million one-off non-cash inventory charge booked last year did not repeat added 315 basis points to the year-on-year improvement. Product and customer mix created a 160 basis point headwind, and we expect that to moderate over time as the mix of consumables and devices evolves and as PromethION margins keep improving. Importantly, the shift to the CapEx pricing model that we began last year, together with yield improvements and consumable recycling, produced a significant underlying margin improvement of 305 basis points. There is more opportunity ahead for PromethION flow cell recycling and further yield improvements, which should support higher margins over time. On the other side, FX was an additional 60 basis point headwind in the period, which at current rates we expect to moderate in the second half. The next slide provides some additional context on how our gross margin profile has developed and where we see further potential over time. As a reminder, our consumable sales represent revenues from MinION and PromethION flow cells and kits. Across consumables, gross margins have risen from 64% in 2023 to around about 75% today. Over the longer term, we believe there is potential to move above 80%, a level we are already achieving across specific product lines.

Nicholas Keher

executive
#9

For devices and services combined, gross margin is up from roughly 23% to about 34% at present, and longer term we can see a route to roughly 40%. What we've gained so far stems from the new pricing model, which has delivered structural gains in product economics, alongside improved flow cell yields, recycling of MinION flow cells and larger scale. Going ahead, we expect additional upside from better yields and flow cell recycling, especially within the PromethION flow cell range, plus SKU optimization and more scale in services. We're not counting on any contribution here from business development activity. We also have known headwinds to handle, notably inflationary pressure on compute and memory costs. Those we're tackling via changes in product development, forward purchasing and pricing. On adjusted EBITDA, revenue growth, gross margin expansion and cost discipline combined to deliver a 54% improvement in our adjusted EBITDA, from GBP -48.3 million to GBP -22.1 million in the period. We also saw a sequential improvement of roughly GBP 16 million in the second half of 2025. Since the close of 2023, our adjusted EBITDA losses have narrowed substantially, mirroring a blend of robust revenue growth, gross margin gains and tighter cost discipline, including the efficiency and strategic realignment programs carried out in 2025.

Nicholas Keher

executive
#10

For the first six months of 2026, adjusted operating expenses declined 7% compared with a year earlier. We anticipate that the year-on-year decrease will shrink toward flat during the second half, even as we keep identifying additional efficiency opportunities as we move into 2027. Above all, our target of adjusted EBITDA breakeven for 2027 is still unchanged, supported by revenue growth, more gross margin expansion initiatives, and ongoing cost control. Now on cash: we finished the period holding $234.5 million in net cash equivalents and other liquid investments, with no debt. That figure was $68.3 million below the year-end level, which mirrors the usual seasonality in our cash flows plus one-offs. Operating cash flow outflow before working capital movements improved significantly, reaching $17.6 million, roughly $27.2 million better than the first half of 2025 and broadly consistent with how our adjusted EBITDA performed. Working capital took in $21.6 million, versus an outflow of just $6.2 million a year ago, and that largely explains why cash performance in the first half came in softer than the second half. The biggest swing was $18.2 million in payables, which encompassed $25.7 million tied to 2025 bonus payments that will, naturally, reverse in the second half. CapEx and capitalized development costs came to $30.1 million, of which the bulk — $24 million — was R&D capitalization, up from $20 million the prior year.

Nicholas Keher

executive
#11

Additionally, $4 million went toward licenses and patents, along with $2.1 million for PPE. Other movements were less significant — tax, for instance, represented a $1 million outflow — though we do anticipate collecting our R&D tax credit during the second half, amounting to roughly GBP 10 million. Cash outflow and assets at customers likewise came down to $2.6 million, materially below the $14.4 million posted two years back in the first half of 2024, prior to our pricing model shift to CapEx first. A modest net inflow of $4.6 million came from other investing and financing items. In the period, we signed a material cross-licensing agreement with a global diagnostics company. That deal combines specific intellectual property from Oxford Nanopore with that of the counterparty, giving it freedom to operate under existing IP while strengthening our overall IP position. Turning to the economics, $20 million of upfront revenue will come to us in 2026, recognized at 100% gross margin. A further $15 million of revenue tied to product purchases is then set to arrive across 2027 and 2028. Beyond that, an ongoing royalty at the low to mid-single-digit level on the counterparty's platform revenue will be paid to us for the life of the patents.

Nicholas Keher

executive
#12

Looking at what analysts expect for the counterparty's product sales, we think the bulk of the economic value—roughly 90% of the arrangement—lies in that longer-term royalty stream. Just to remind everyone, our FY 2026 guidance of 16%-20% constant currency revenue growth does not include the $20 million upfront. Royalties will also be additive to that guidance as they are earned, and they are not included in FY 2026 or in the medium term at all, since we cannot reliably forecast the counterparty's future revenue from the platform right now. Today we also signed a new cross-licensing agreement with a global diagnostics company, which we believe could be potentially transformational for the group's outlook. On the economics, we are set to receive a $20 million licensing fee, recognized during the second half of 2026 at 100% gross margin. There will also be an additional $50 million in committed product purchases, recognized over 2027 and 2028, which analysts and investors should model at our current group margin. On top of this, we will also receive a net royalty calculated as a low to mid-single-digit percentage of revenues generated by certain life science and diagnostic products incorporating the licensed intellectual property for the life of the license patents.

Nicholas Keher

executive
#13

Given what the market anticipates for the products covered by this agreement, we think the great bulk of the economic worth—roughly 90%—resides in that royalty stream over the long term. Just to remind you, our FY 2026 guidance of 16%-20% constant currency growth does not include the $20 million upfront. Royalties will likewise be incremental as they are earned and are excluded from our 2026 or medium-term guidance, since these aren't our products. In our view, beyond the financial upside, there's a compelling strategic case for the deal, which strengthens our IP position as well. Moving to FY 2026 guidance. For our core business, guidance stays at 16%-20% constant currency revenue growth, consistent with the trading update. We still expect to deliver gross margins of approximately 62%, consistent with the original guidance and the first-half performance. Adjusted operating expenses are now projected at negative 2% to flat year-on-year, versus the original guidance of 0%-5% growth we provided in March. Looking ahead to the second half, we have substantial revenue coverage that supports our 16%-20% guidance range from business already confirmed, before adding pipeline opportunities. In proportional terms, that amounts to the same coverage level we had entering the second half of 2025, which gives us confidence in the full-year outlook.

Nicholas Keher

executive
#14

And that includes the $20 million upfront payment from the global diagnostics company, which works out to a 680 basis points improvement in incremental constant currency revenue growth for 2026. That raises our top-line constant currency growth expectations from 21%-25%-23%-27%, respectively. Since that $20 million upfront payment carries a 100% gross margin at recognition, it will add 200 basis points to gross margins, taking the 62% reported number up to 64% overall. Together, these deliver a material improvement in the adjusted EBITDA loss for 2026, with efficiency work continuing beyond. I will now hand things over to Francis Van Parys to walk through our updated strategy.

Francis Van Parys

executive
#15

Thank you, Nick. Four factors give me confidence in what Oxford Nanopore can become. First, this kind of opportunity is familiar to me. My career in life sciences spans over 20 years, across GE HealthCare, Cytiva, and Radiometer. A lesson those businesses taught me is that great technology opens the door, yet it is customer adoption and execution that decide how much of the opportunity you ultimately capture. Biacore is especially relevant. It was a highly respected research platform with excellent science. We preserved that strength in discovery research while expanding into adjacent regulated markets such as biomanufacturing and quality control by aligning the offering much more closely with customer needs. At Oxford Nanopore, I see a similar opportunity. We have a differentiated sensing platform, a strong position in research, and significant potential to broaden adoption in markets such as biopharma and clinical. Second, we have global reach. I have led businesses across Europe, Asia, and North America, and Oxford Nanopore already has a customer base and commercial presence across those markets. Third, much of the difficult technology work has already been done. The platform exists, the science is proven, and the customers are using it today. Finally, I believe there is significant headroom between what the technology can do and the value the business captures today.

Francis Van Parys

executive
#16

I don't see a business that has to reinvent itself. What I see are solid foundations and a real chance to convert more of that technological edge into value for customers and into growth that lasts. In its previous phase, Oxford Nanopore was focused on demonstrating just how remarkably broad this technology's capabilities are. The coming phase is about deciding where we can deliver the most value to customers and then winning in those areas. That's the opportunity. Yet to capture it, we must also be honest regarding where we stand right now and what has to change. During my first few months at Oxford Nanopore, I've carried out a thorough review of the business. My takeaway is simple. The foundations are solid, yet we aren't yet turning those strengths into adoption and growth at the level we ought to. Customer interest in the platform is strong, but adoption is still short of its potential, and the experience customers have has not always been as consistent as it should be. Our technology is highly differentiated, yet at times our product roadmaps have been shaped more by what science makes possible than by the customer problems we are trying to solve. We hold a wide range of opportunities, but that breadth has not always been accompanied by enough portfolio focus, clear choices, and operating discipline.

Francis Van Parys

executive
#17

We do have skilled, deeply dedicated teams, yet to scale adequately we require more leadership depth and stronger capabilities. Reaching that goal does not mean reinventing Oxford Nanopore. What it does mean is being far clearer regarding where we concentrate, more intentional about translating innovation into customer value, and more consistent in execution. Those findings have informed the strategy I will now walk you through. Sustainable, profitable growth is our aim, and our approach rests on four pillars that reinforce one another to create shareholder value. Customer-centric growth comes first. We will direct our resources toward high-value applications in which our technology clearly has the right to win. We will deepen our grasp of customer needs, craft clearer value propositions, and collaborate with customers and third parties so that adoption speeds up and widens. Focused innovation is second. We will keep investing in our differentiated technology platform, though with a sharper commercial purpose. Our product and technology roadmaps will be tied more tightly to what our priority customer segments need, with greater emphasis on dependable, robust, and easy-to-use products and workflows. Near term, that emphasis falls more on enhancing product performance and workflows than on developing entirely new products.

Francis Van Parys

executive
#18

Number three is disciplined execution. We're going to simplify the portfolio, make our operating model stronger, and bring in clearer ownership, standardized processes, and more consistent performance measures that line up with our strategy. Portfolio simplification is already underway, and we're already changing the way we work. This is about making execution more predictable and building a business that can scale efficiently. Number four is a high-performance culture, which underpins the other three pillars. We'll keep building leadership depth, adding talent, and strengthening the commercial, operational, regulatory, and GMP-ready capabilities required to scale while retaining the ambition, agility, and innovation that makes Oxford Nanopore distinctive. These are not separate programs. Our market choices determine where we focus innovation. Focused innovation creates products and workflows that address priority customer needs. Disciplined execution allows us to deliver consistently and at scale. Our culture and capabilities determine how effectively we bring the strategy together. The strategic direction is now clear. We are now in the process of operationalizing it, translating these priorities into specific portfolio choices, refining our go-to-market approach, product roadmaps, operating plans, milestones, and measures of progress. Today, I will go into more detail on the first and fourth pillars, customer-centric growth and high-performance culture.

Francis Van Parys

executive
#19

The first one lays out where we'll concentrate and the way we plan to succeed. The fourth covers the organization, leadership, and capabilities required for delivery. Regarding focused innovation and disciplined execution, the direction is similarly clear and work has begun. We're currently converting those priorities into detailed operating plans and establishing suitable governance processes. Once that operationalization has progressed further, we'll come back to those pillars and can lay out the outputs, milestones, and measures investors should use to judge our progress. Let me start with customer-centric growth — where we'll focus, why we think we can win, and how those choices underpin our long-term growth ambitions. I'll begin with how we determine where to participate. For every application, we evaluate two things: how differentiated our technology's value is and how readily the opportunity can be realized. Differentiation lacking a credible route to adoption isn't sufficient. Likewise, an appealing market in which we contribute minimal differentiated value isn't a strategic priority. Our right to win is greatest where richer biological insight, speed, flexible deployment, and easier adoption meaningfully alter the customer's decision. The research market falls squarely within our present sweet spot, where end users prize new biological insights for discovery purposes.

Francis Van Parys

executive
#20

When it comes to particular biopharma workflows, we're also seeing robust differentiation and a believable route to adoption. Clinical presents a substantial opportunity, yet a lot of workflows come with a heavier load around evidence, regulatory, reimbursement, and market building, which means the right way to participate is frequently different. This slide gives a simplified picture, organized into wider end markets drawn from the detailed analysis underpinning each application area — customer needs, adoption requirements, competitive dynamics, and expected returns all included. The guiding principle is simple: put the most investment where we can deliver distinctive customer value and a credible return. Turn to collaborations when they can speed up access or ease the burden of adoption, and stay selective in other areas. That evaluation then shapes the way we participate. There's no requirement for us to build and own each element of every solution. At one extreme, we can enable others via licensing, technology transfer, or off-the-shelf compatibility, using relatively limited capital. Moving further along, OEM co-development or commercialization arrangements become an option. Where our differentiation is at its strongest and we hold the capabilities to do so, we can own the complete solution and capture the product economics directly. Investment level, control, and value capture all climb as we move along that spectrum. For research and core biopharma QC workflows, the argument for a fuller Oxford Nanopore solution is at its strongest.

Francis Van Parys

executive
#21

When it comes to clinical, routes led by partners tend to be the better fit, since validation, regulated deployment, and access to channels make up a substantial share of the solution. That kind of approach lets us scale in a smart way—keeping control where it counts, while drawing on outside capabilities where they boost speed, reach, or returns. The same reasoning holds throughout the customer workflow. Library preparation, sequencing, and base calling form our differentiated core. Around that core, customers require sample collection, extraction, preparation, automation, analysis, interpretation, and integration with the systems they already run. We'll build where Oxford Nanopore holds a clear advantage, yet we won't duplicate capabilities that others already provide well. In research, biopharma, and clinical markets, specialist third parties can make workflows simpler to deploy and widen our reach into customers and channels. Collaboration for its own sake isn't the objective. What we're after is a more complete, dependable customer solution, with clear accountability across the end-to-end experience. That lets us concentrate our own investment on the platform and the priority workflows where we create the most value, while specialist capabilities are used to remove adoption barriers. Pulling those choices together gives us a focused path to 2030. The total market is very large, but pursuing all of it is not our strategy.

Francis Van Parys

executive
#22

We’ve pinpointed a serviceable market worth roughly GBP 14 billion to GBP 16 billion, and inside it there are three priority areas we can pursue organically right now: research whole genome sequencing, biopharma, and selected clinical. Research currently represents around two-thirds of group revenue. That is our biggest market, a core strength, and a significant growth contributor. As time goes on, we anticipate a more balanced mix. Clinical and biopharma are starting from smaller bases, yet we expect them to expand more quickly and to account for roughly two-thirds of group revenue by 2030. The chart illustrates the direction of travel, not precise end market guidance. What matters is that we are not depending on a single market. We are sustaining and expanding the research franchise while building scale in the faster-growing areas where our technology has a clear right to win. That shifting mix underpins our path to more than GBP 700 million of organic revenue by 2030. Business development, licensing, and royalties may offer further upside. The following slides set out where we will concentrate within research, biopharma, and clinical, and what has to be true for adoption. Research is our strongest position today and stays a central element of the growth plan.

Francis Van Parys

executive
#23

Our focus is on applications in which long reads along with native methylation genuinely alter the biological answer. That means large genome centers, biobanks, core labs, and disease research programs working with structural variation, phasing, difficult loci, and complex genomes. Read length alone is not where our edge lies. What sets us apart is combining long and ultra-long reads, phasing, and methylation within a single flexible workflow, from exploratory studies all the way through to larger production-scale cohorts. The path to scale is evident: a stable, production-ready PromethION workflow, prioritized bioinformatics, robust support, and visible roadmaps for priority customers. We also must keep enhancing output and cost per genome while generating evidence showing the added utility that long reads and methylation deliver. Methylation stands as one of the clearest illustrations of differentiated product utility at Oxford Nanopore. The underlying code is what DNA sequence tells us. How that code is being expressed is something methylation helps reveal, and it can separate healthy from diseased biology. Sequence and native methylation can be captured by Oxford Nanopore within the same run, with no separate assay or consumable required. Commercially, that matters, since it lets us build products and workflows that legacy approaches find harder to replicate. Four panels are already shipping, among them methylation, pharmacogenomics, and cancer digital panels, and tumor profiling is expected from the second half.

Francis Van Parys

executive
#24

The Prader-Willi case shows the clinical value that's possible. The sequence by itself didn't give us the answer, but methylation phasing uncovered the underlying cause. That's the way we think about turning technology leadership into product leadership — building distinctive, saleable applications that provide more information without adding an extra workflow or consumable. Among our priority end markets, biopharma is growing fastest and stands as a meaningful long-term opportunity. Our focus is on controlled R&D and QC workflows in which today's approaches depend on multiple assays, multiple vendors, and multiple handoffs. That fragmentation means long turnaround times, considerable labor, and a heavy integration burden for customers. Native long reads can supply richer context around constructs, cut down on reconstruction in complex libraries, produce results more quickly, and, in selected workflows, bring identity, integrity, purity, and contaminant readouts together into a single test. Our participation model is going to be selective. We plan to build and support core QC workflows ourselves, while relying on channel and service provider routes for broader R&D applications. The work ahead is clear: kits, productized bioinformatics, a CFR-ready instrument path, strong comparative evidence, and a focused go-to-market plan. This slide makes the biopharma opportunity concrete through a specific mRNA quality control case study. At present, manufacturers frequently rely on a series of separate instruments and assays to evaluate the critical quality attributes of an mRNA product.

Francis Van Parys

executive
#25

Identity, integrity, and purity might each call for distinct approaches, separate data systems, and several handoffs. What we've shown is that one Oxford Nanopore run can bring together multiple quality control measurements, giving a comprehensive view across a range of attributes, with the outputs combined into a single report. That makes the potential customer value very clear. A simpler workflow, faster results, fewer methods to maintain, and a more complete picture of product quality. The next step is to take that demonstrated capability and productize it into a dependable, validated, and audit-ready workflow that biopharma customers can adopt with confidence. This is a good example of focused innovation in practice: start with a customer problem where our technology can do something distinctive, demonstrate its capability, and then turn it into a product and workflow that can be adopted at scale. Clinical is a significant opportunity, but we'll approach it with discipline. We'll focus on selected workflows where richer information or speed can change a clinical decision. Rare disease and rapid whole genome sequencing, tumor profiling, and selected acute infectious disease applications. The technology has a clear role. Long reads can resolve structural variants, repeats, phasing, and difficult genes. Native methylation can support tumor classification, and adaptive sampling and flexible devices can improve speeds and deployment.

Francis Van Parys

executive
#26

However, clinical adoption has a gate. It demands locked workflows, reporting at clinical grade, integration with labs, evidence, health economic utility, and trust. So our model will pair Oxford Nanopore-led enablement in specialist centers and reference laboratories with partner-led IVD and channel routes in cases where wider deployment needs capabilities past our core. This is a targeted enablement strategy, not an effort to build every clinical solution in-house. Here's another illustration of what the platform already handles when pointed at a particular customer workflow. In this acute leukemia study, eight distinct conventional pathology assays were folded into one Oxford Nanopore adaptive sampling run. Out of that single run came nine categories of outputs, among them copy number variants, methylation, and pharmacogenomics, at an indicative cost of roughly $350-$450 per sample, versus approximately $1,650-$2,050 across the conventional assays. The study shows how the platform can consolidate multiple tests into a single workflow while delivering richer information and potentially much lower costs. The opportunity now is to take demonstrated capabilities such as this and turn them into validated, reliable, integrated workflows that can be adopted more widely. That's precisely the kind of application we intend to prioritize, where our technology's differentiation becomes a clear and tangible benefit for the customer.

Francis Van Parys

executive
#27

That lays out where we'll concentrate and how growth centered on customers will be delivered. Picking the right markets is only one piece of the puzzle. We also require the leadership, the capabilities, and the culture to carry out those choices consistently and at scale. That's the reason a high-performance culture forms the strategy's fourth pillar, and why reinforcing the leadership team was an early priority. We've already achieved notable progress. We're building on an experienced leadership core, including Nick, who leads finance and operations, and Lakmal, who holds the longest tenure with the company and leads science. Over the last few months, we've brought in significant capability across the executive team, including new leadership in people, medical, and information technology. Tina St. Leger has joined as Chief People Officer, Andrew Watson as Chief Information Officer, and Davide Manissero as Chief Medical Officer. Conor McKechnie will come on board in October as Chief Marketing and Communications Officer. Taken together, the existing team plus these new appointments reinforce the leadership depth and functional experience required for the next phase of Oxford Nanopore's development. This isn't simply a question of who sits on the executive team. It's about how the whole organization operates, how clearly we set priorities, how close customers and markets are to our decisions, how quickly decisions get made, and how effectively teams work together.

Francis Van Parys

executive
#28

So that's why, in addition to beefing up the leadership team, we took a hard look at our culture and heard directly from employees right across the organization. That wider perspective, plus input from our people, confirmed the very same themes that emerged during the strategy process. There's strong alignment throughout the organization on the priorities we've pinpointed. Focus comes first. We have to get the organization aligned behind fewer strategic priorities, so people know exactly what matters most and where we're choosing to put our time and resources. Second, we need to draw our customers closer into decision-making and product development, so customer needs carry more weight when priorities are set across the organization. Third, accountability needs to be clearer and decisions need to move faster. As we scale, clear ownership ought to help us decide quicker and execute with more consistency. Fourth, collaboration between teams has to get stronger. A lot of the outcomes our customers need span R&D, product, commercial, and operational teams. So those teams need to work together more effectively. Last, we have to simplify how we work, building a more agile and responsive organization without piling on unnecessary bureaucracy. The employee survey results handed us a useful baseline.

Francis Van Parys

executive
#29

Participation came in at 67%, positive engagement reached 75%, and 73% of employees indicated they would recommend Oxford Nanopore. That gives us a solid base to work from, though it also sets out a clear agenda for change. What we're focused on now is turning those themes into action — getting the organization aligned behind a strategy, tightening accountability and collaboration, and making it simpler for teams to deliver for customers. That matters a great deal when it comes to building the high-performance culture required to support the next phase of growth. Let me turn now to linking the strategic choices with the financial framework. For FY 2026, guidance is 16%-20% constant currency growth, which works out to roughly GBP 260 million-GBP 269 million, or $345 million-$355 million in revenue. We've now laid out a view on the priority applications where we see the biggest opportunity across research, biopharma, and clinical, along with the potential to build toward more than $700 million of revenue by 2030. Research is our biggest market today and will keep contributing significantly through 2030. We expect it to grow at a slower pace than clinical and biopharma, but off a considerably larger base. Clinical and biopharma should grow more quickly and account for a bigger share of group revenue, while industrial keeps delivering steady single-digit growth.

Francis Van Parys

executive
#30

That evolving mix underpins group organic revenue growth of more than the mid-teens starting in FY 2026, and that rate will climb as higher-growth markets take on greater weight. Our target by 2030 is revenue exceeding $700 million. This projection does not depend on business development, licensing, or royalty opportunities that may arise later, which could deliver extra upside. It is worth noting that the $20 million upfront payment tied to the cross-licensing agreement sits outside this organic framework and outside the FY 2026 guidance. By FY 2030, we anticipate adjusted EBITDA margins exceeding 15%, along with free cash flow that is positive and growing from FY 2028. A disciplined approach to capital allocation underpins that financial framework. Organic investment in the core business comes first — funding the innovation engine, the product and workflow roadmaps behind our priority applications, and the manufacturing capacity needed to scale. Money will go to programs with evident customer value and commercial potential. Second, we will use partnerships as strategic enablers. Where collaboration can widen the serviceable addressable market, eliminate a workflow or adoption barrier, or speed up access to customers and channels, we will invest. We will judge these opportunities against clear strategic and financial criteria, among them a target return on invested capital exceeding 15%.

Francis Van Parys

executive
#31

Third, we'll look at selective M&A in cases where it can speed up adoption or reinforce where we stand in a priority application. That should sharpen our capacity to grow more quickly and bolster Oxford Nanopore's strategic capabilities. A strong balance sheet supports all three priorities. Keeping financial flexibility matters, given the variability across our markets and the investments needed to deliver the strategy. The principle is straightforward: put capital behind the areas where Oxford Nanopore has the clearest right to win, bring discipline to every investment decision, and safeguard the balance sheet as we build towards our 2030 targets. Let me close with three key takeaways. First, Oxford Nanopore has strong foundations and a significant opportunity ahead. We have a differentiated technology platform, a global customer base, and clear areas where that technology can create distinctive value for customers across research, biopharma, and clinical markets. Second, we now have much greater clarity about how to turn that opportunity into sustainable, profitable growth. We are making clearer choices about where we compete, focusing innovation more closely on customer needs, strengthening execution, and building the leadership and capabilities required to scale. The direction is clear, and we are now operationalizing the strategy across the business.

Francis Van Parys

executive
#32

I’m eager to keep you updated at the appropriate time about the progress we’re making—especially when it comes to focused innovation and disciplined execution. Third, we’ve established clear financial milestones. By 2030, our targets are revenue of more than GBP 700 million, an adjusted EBITDA margin above 15%, and free cash flow that is positive and growing. Those goals don’t depend on future business development, licensing, or royalty opportunities, which could offer additional upside. 2030 isn’t the endpoint. It’s a key milestone on the path to a longer-term ambition I laid out at the start: building Oxford Nanopore into a business with revenue of GBP 1 billion+. I’m an operator at heart. I’m competitive, pragmatic, and focused on execution. There’s substantial work ahead, and I’ll be transparent about where performance needs to improve and decisive about the changes required. But we have strong foundations, clearer priorities, and an organization we’re strengthening so it can deliver against them. My confidence comes from that combination—the quality of the technology and the opportunity in front of us—but also from much greater clarity about where we’ll focus, how we’ll win, and what we need to do differently to create sustainable value for customers, partners, and shareholders.

Francis Van Parys

executive
#33

Thank you. Nick and I will now take your questions.

Operator

operator
#34

Thank you so much, sir. Ladies and gentlemen, if you'd like to pose an audio question, simply press star one on your telephone keypad, and please confirm your line is unmuted so your signal can reach your equipment. So, once more, star one for questions. Today's very first question comes from Zain Ebrahim at JPMorgan. Go ahead, Zain. Your line is open.

Zain Ebrahim

analyst
#35

Hi, everyone. Thanks for taking the questions. This is Zain Ebrahim from JPMorgan, and I'll try and stick to two. My first question concerns the royalties on the diagnostics agreement you signed today. Could you just walk us through that agreement in more detail, and how we should think about the durability of the royalties tied to the agreement? You mentioned it is over the course of the IP, so should we assume 10 years or even longer than that for modeling? And how meaningful could the royalties be to your 2030 outlook? I know you mentioned it is about 90% of the NPV, but any further color there would be helpful. My second question is on the clinical biopharma strategy, which was helpful to understand more from the presentation. You mentioned it will be about 2/3 of revenues by 2030. Just to clarify, how much of that expectation is de-risked by collaborations that you have already signed so far? You are already delivering strong biopharma revenue growth now, but the guidance or target in 2030 seems to imply an inflection in revenue growth for biopharma. So when can we expect to see that inflection?

Francis Van Parys

executive
#36

All right, thanks, Zain, for that question. I’ll make a brief comment on the first one, and then I’ll let Nick provide a bit more detail. For us, this is a significant agreement. It shows that our IP portfolio is strong. It’s one of the participation models we believe is highly relevant to how we take part in the market. We’re happy about the potential impact it could have, and we think it could be quite instrumental for us as a company. Nick?

Nicholas Keher

executive
#37

Yes. Thank you, Francis, and thank you for the question, Zain. There's a limit on how much detail we can share, and we want to respect the confidentiality of the agreement we've signed. That said, we fully recognize the need to balance that against making sure investors and all of you get the information required to model this going forward. On the royalties themselves, low to mid-single digit. For significant growth in the products this covers through 2030, market expectations is all we can point to. So it's a fairly large contributor — kind of transformational, in fact — potentially for our P&L as well, with the drop-through carrying 100% gross margin. On how long the patents within it last, obviously we can't provide firm dates there. We don't believe that would be appropriate. But if you think past the usual forecast horizon you've discussed, so past that 10-year period, I think that's where we should be looking, and a quite long duration indeed. Of course, as everyone knows, patents typically carry a 20-year life. It won't be that long, but it's closer to that end than to the 10. You're absolutely right.

Nicholas Keher

executive
#38

If you combine every one of those elements, what becomes clear is that 90% of the economic value here sits in the royalty stream rather than in the upfront payments and product purchases.

Francis Van Parys

executive
#39

Thanks, Nick. Regarding your second question, I believe it's worth noting that the high-value applications we're going after—the ones we've discussed, including clinical and biopharma—by our estimate currently make up roughly 40%-45% of group revenue, and by 2030 that should rise to something closer to 65% of group revenue. The biopharma and clinical opportunities are growing at rates in the high-single-digit range. They're already expanding quickly, and as they take on greater importance and account for a larger share of group revenue, we anticipate our overall growth rate will speed up. When it comes to collaborations already announced and signed, we've publicly discussed several in the clinical space. A number of others are in progress, and roughly 20 biopharma customers are validating us right now. We can't name them, but they are actively assessing our technology and putting it into their workflows. We estimate—and we're quite confident about the execution of that activity and the share it will represent of the more than GBP 700 million we're targeting by 2030.

Nicholas Keher

executive
#40

I'll just add a little to that.

Zain Ebrahim

analyst
#41

Much appreciated.

Nicholas Keher

executive
#42

Oh, my apologies, Zain. I’d also like to add a bit more on that revenue split. Right now, 35% comes from applied markets, and that shifts to 65% by the 2030 timeframe. On the biopharma side, there are clearly 2 elements. There’s the QC side that we have with the evaluators, but we also see a very significant opportunity in the R&D space.

Zain Ebrahim

analyst
#43

Got it. Thank you very much.

Operator

operator
#44

Thanks a lot, sir. The next question comes from Kyle Mikson at Canaccord. Kyle, go right ahead.

Kyle Mikson

analyst
#45

Hi, guys. Thanks for the questions. Congratulations on the quarter's margins and profitability—and all this color in the deck is great. For my first question, I wanted to ask about the near-term outlook. Underlying growth in this kind of medium-term guidance looks like high teens. Is that a good way to think about FY 2027 growth? On the street, consensus sits at 20%, so I'm just curious, given probably a more favorable comparison to 2026. On this note, when you think about maybe beyond 2030, it looks like clinical, you're being a little maybe conservative. How does clinical sort of expand meaningfully beyond this medium-term forecast as well? Thanks. Then follow up.

Francis Van Parys

executive
#46

Thanks, Nick.

Nicholas Keher

executive
#47

Yes, thanks. Regarding your first question about the near-term outlook — mid-teens and accelerating, I think that's a key point here. You're absolutely right. There are a few moving pieces, so please bear with us. We have 2026, where we have 16%-20%, almost like underlying growth for the core business. Then there's this GBP 20 million of non-recurring revenue that comes on top, which brings us to that 23%-27% for this year. As we move into 2027, we have that core growth rate of, let's say, 16%-20%. From that, we expect mid-teens growth in 2027, and then acceleration as we get to greater than GBP 700 million in revenue, that is, by 2030. Consensus is at 20% today for next year. I would also just note that our guidance assumes nothing for royalties from the global diagnostics company we have signed the agreement with, or from any other future business development activities we are looking at. I just want to make sure people kind of capture that in their models — that this will be additive overall. Beyond 2030, I know Francis will add to this, but just from the shape of the model, you are absolutely right. There is a lot for us to do in the clinical space, and we have very high confidence in the adoption that we can see coming through.

Nicholas Keher

executive
#48

When it comes to some of those development opportunities, especially with peers, for some of them the traction will really only start building perhaps past 2030. I think it's quite fair to say that, yes, the biopharma piece is absolutely critical to that 2030 horizon. Clinical is a bigger opportunity over the longer term, so it's more that the growth rate will keep accelerating past 2030 and what our model expectations are. Francis?

Francis Van Parys

executive
#49

Sure, so from now through 2030, the largest share of our growth is going to come from biopharma, since that's the opportunity closer at hand. Clinical represents the bigger opportunity overall, and when you consider market segments such as infectious disease, that's where we'll probably shift toward an IVD-style approach by way of partnership. For those developments and products, along with the regulatory requirements needed for them to generate truly meaningful revenue, they sit in the outer years, and so growth will ramp up considerably past 2030.

Kyle Mikson

analyst
#50

Appreciate it. As a follow-up, I'm taking a look at R&D expense, which has come down quite a bit of late—especially during the first half of 2026. Clearly, that moves you closer toward the adjusted EBITDA to cash flow target, which is excellent. Still, I'm wondering how essential the pipeline work is to the medium term—the 2030 targets, I suppose—things like the PromethION Q-Line, which is likely nearer term, and then protein sequencing as well. That one is obviously longer term. I'd like to hear about those efforts and how you might invest going forward.

Francis Van Parys

executive
#51

Right. So in the near term, we expect R&D expenses to be pretty much where they are at the moment. Obviously, as part of prioritizing our R&D products, prioritizing projects, we'll make some changes. We'll make some adjustments, but that doesn't affect the total spend in the near term. We expect the spend to then, beyond from 2020 to 2028, evolve as we grow revenues. We are committed to our protein program, as an example. So we expect that it will then continue to be an important part of our investments as we continue to invest in the platform. Nick, do you want to share more details on that?

Nicholas Keher

executive
#52

Yes, definitely. I mean, innovation that's pivotal is essential to this company and to what we achieve, so we will keep putting money into it at all times. Regarding the main items you brought up there, certainly. That's part of the planning we're working through right now. As Francis mentioned, we'll return with additional specifics on pillar two and pillar three, and those will sort of contribute to this too, Kyle. But as far as what we've achieved so far, as you're aware, we carried out a fairly major strategic realignment exercise last year in which we chose to halt certain activities, and you're now seeing the payoff from that. As we go about finishing the operationalization of the strategic plans that have been laid out, we'll return with more specifics once again. Definitely before our full-year results, where we'll lay out a bit more. Still, we aren't saving our way to greatness here. What we're really doing is concentrating and moving capital toward the higher ROI activities, and the items you mentioned are plainly on the roadmap.

Kyle Mikson

analyst
#53

That’s great. Thank you, everyone. I appreciate it.

Francis Van Parys

executive
#54

Thanks a lot, sir.

Nicholas Keher

executive
#55

Thanks.

Operator

operator
#56

The next question comes from Jon Unwin at Barclays. Go ahead, please. Your line is open.

Jon Unwin

analyst
#57

Hi, guys, it's Jon from Barclays. Thanks for taking my questions. One on 2027 revenue and then on gross margin, please. Just on 2027, given you're forecasting to grow 16%-20% constant currency this year, if you grow mid-teens in 2027, what would be causing that year-on-year deceleration in growth? The GBP 15 million of committed product revenue that you have over the next couple of years, just to confirm, that is included in your growth expectations for next year in 2028, but that you might also see on top of that some royalty income, which is not included. Then on the gross margin, where do you think gross margin can get to in 2027, given your lowered revenue expectation, but recommitment to the adjusted EBITDA breakeven? And would you have been able to achieve that adjusted EBITDA breakeven next year without this new licensing contract and the committed product revenues that you have got? Thank you.

Nicholas Keher

executive
#58

Okay. Jon, I believe that covers roughly five questions, so I'll simply take them one at a time. Let's start with 2027 revenue and gross margins. To begin with, the $15 million in product revenue stemming from the cross-licensing arrangement is part of that mid-teens revenue expectation, and it then accelerates. Royalties are excluded from that. Royalties sit on top of both the 2027 outlook and the medium-term outlook, and even the 2026 figures we are discussing. The rationale there is that attempting to forecast revenue expectations for this would be genuinely inappropriate on our part, and the market would have priced that in regardless. Regarding how far gross margin can climb in 2027, that is precisely why we included this slide covering the progress achieved to date. So on consumables, gross margins have reached approximately 75%. As you would expect, that reflects a blend across MinION, PromethION, and kits. On MinION, the teams have done a remarkable job, essentially through the recycling efforts, and we already exceed that medium-term target of 80%. On PromethION, the teams are addressing this as well, and basically they are progressing toward recycling at greater volumes on the PromethION flow cell, which will deliver a meaningful benefit to gross margin.

Nicholas Keher

executive
#59

We're actually hitting certain recycling percentages at this point already. When it comes to devices and services, it's really about scale plus services. And on devices, as the industry does, we clearly see headwinds when it comes to compute costs. We see headwinds on items such as memory costs. We're offsetting a portion of these via development work aimed at lowering our cost of goods, so pricing doesn't have to be a concern for us. In some cases, pricing may need consideration too. Even so, we continue to believe that 40% gross margin is achievable over time. At this point it becomes a linear equation regarding what the mix looks like next year. But as far as where we stand right now, 62% this year, we see meaningful improvement available for next year too. So yes, we saw a 400 BPS improvement this year alone. Thinking about that kind of improvement going forward may not be unreasonable either. Do we need this royalty agreement to reach adjusted EBITDA breakeven? No. Will it help? Well, yes. Will it be additive to this? Yes. And we truly hope the market and investors grasp what this deal could mean for us, which is transformational for the company's profitability.

Nicholas Keher

executive
#60

Jon, is that all of it, or did I leave one out?

Jon Unwin

analyst
#61

On one slide — and I believe this came up among the original seven questions I raised — if you're looking at mid-teens growth next year while doing 16 to 20 this year, would it be fair to think growth could decelerate next year, X, the royalties, and is there any reason for that?

Nicholas Keher

executive
#62

Yes. Sorry, Jon, I missed that one. The reason is that, in doing this work, what we've done is examine fundamentally every application our customers are running on the platform today so we understand precisely what they're doing now. We also have our pipeline, which is very material, of opportunities we've reviewed, and it splits the same way as the applications people are working on. Having looked at that, what we've done is we have roughly 40%-45% of our business inside those target applications, and that part is growing very quickly, and then we have, if you like, all the remaining application areas, where we're being prudent about what could happen there in terms of growth rate. Because if we wind up assuming that the halo effect from these efforts we're making produces a significantly above-market growth rate for these other application areas, where we won't have the same level of focus, then we could wind up getting caught out. What we're really doing is being prudent on that 55%, 60% of the business, and we also recognize that it could take a bit of time before refocusing the company, the organization, on those target applications begins to generate the results we want.

Nicholas Keher

executive
#63

Right now we’re simply taking a cautious stance. We really don’t want to see things slow down to that mid-teens level, but it wouldn’t be appropriate for us to put anything out there at this point. Naturally, we’ll return at the full-year results and give detailed in-year guidance as well.

Jon Unwin

analyst
#64

I appreciate that.

Operator

operator
#65

Much appreciated. Now we'll move on to Veronika Dubajova at Citi. Go right ahead, Veronika — your line is open.

Veronika Dubajova

analyst
#66

Hello there, and good afternoon, everyone. Thanks for taking my questions. I've got two, if I may. The first is for you, Francis. Taking a broader view of R&D, what would you identify as the priorities as you move the business forward over the medium term? Where would you want those R&D pounds to go, and what do you see as the major opportunities? And perhaps linked to that, we've already seen some pruning of the portfolio — are there any further opportunities among the future development projects that you think might be discontinued or cut? Then my second question is for you, Nick, about the very impressive OpEx control we saw in this half year. Could you give us a bit of flavor of what's enabling you to bring that guidance down in terms of OpEx growth, and any other major opportunities you see for further cuts to operating costs? Thanks, guys.

Francis Van Parys

executive
#67

Thanks, Veronika. Let me return to that first question about R&D, and I appreciate it. As I said earlier, our view is that R&D spending sits at pretty much the right level, though the priorities have to line up more closely with the customer needs we pinpointed in our high value target applications. That's the effort we're in the middle of right now, and we'll bring additional detail when we report full-year results. Our ambition is to return with a finalized plan and clarity on our product roadmap, portfolio simplification initiatives, and so on. Just to give you a flavor of how I see it near term: as we work through what our customers need in those high value target applications, those needs aren't driven by new products. What drives them is product enhancements, workflow completions, and making sure we have a consistent, robust, easy-to-use workflow on our current platform. That will drive a number of enhancements, and refocusing our efforts on making sure we make those happen first. Over the medium term, I also don't see a need to develop new platforms to execute on this strategy. We are pretty happy with where we are with the technology. Customers are adopting.

Francis Van Parys

executive
#68

We simply haven't realized that opportunity's full potential yet, and to get there, I think we have to make sure we build out the capabilities that those markets and those market segments demand. Over the longer term, we're committed to making sure the platform's capabilities keep evolving. Earlier on this call we talked about protein. At some point that's going to become a significant opportunity, and we're committed to carrying on with our investment in that area. What I think you're hearing, and what you'll see — and when we report out in more detail on our future R&D spend — is that this is more about pruning, focusing toward the right customer segments. Then, from the standpoint of portfolio simplification, that work got started last year. We've already put out a couple of announcements on that. I don't think it amounts to a material wholesome change. We're happy with the portfolio we have today, and some of it needs additional investment when it comes to future upgrades. But compared with where we stand today with our platform, we don't expect a wholesome change. There are a couple of additional adjustments involving smaller programs that we'll communicate, but most of the portfolio simplification work that began last year is underway and will soon be finalized.

Nicholas Keher

executive
#69

And regarding your second question on OpEx control — what is it that lets us do this? During the last year we carried out two fairly painful exercises inside the company, and the second one was the strategic realignment effort aimed at sharpening focus on the portfolio and on the R&D projects we had underway. Those benefits are showing up now. We did the same thing — and it wasn't only R&D, it spanned SG&A too — and the gains are visible there as well, which has given us room to reallocate capital internally. With investors and the market, we've definitely tried to say what we do and do what we say, building trust, and I believe we're demonstrating that. That's why, frankly, we're somewhat disappointed by how the top line came in during the first half. But on the OpEx side, we committed to being cost disciplined, and we've shown that ahead of expectations. Looking ahead to next year, or to the second half of this year and the year beyond, I believe we have internal buy-in on exactly how we'll keep driving greater internal efficiency with our capital. The major items appear to be logistics costs, where there's more for us to recover than we currently are, and that sits reported within the sales and distribution line.

Nicholas Keher

executive
#70

Now, regarding areas such as total IT spending, software, and so forth, we've already been taking internal steps to examine this. We can see already that duplication exists with programs we have in-house. That's a big number. Over the coming six months, we're going to execute on that, and next year you're going to see the benefits of it in the numbers as well. These things are going to let us reallocate capital and essentially focus on the higher growth ROI activities, essentially as we're doing in R&D as well. So we're pleased with how we've gone. We'll continue to try and do better than what we're guiding to on the OpEx line as well.

Veronika Dubajova

analyst
#71

Understood. Thanks, everyone.

Operator

operator
#72

Much appreciated for those questions, ma'am. The following question comes from Sam England, who is an analyst with Berenberg. Kindly proceed.

Sam England

analyst
#73

Hi folks, appreciate you taking my questions. On the first one, you mentioned the pickup you expect during the back half of this year, driven by a combination of booked business and pipeline. Could you give us a feel for how the second half has started out and how much you're counting on converting that pipeline to reach the full-year figure, just so we understand today's visibility? Then on a longer-term point, could you discuss your thinking on the research market as it relates to that 2030 revenue goal? I guess, how much conservatism do you figure you've built in, given all the uncertainties right now? Is there a chance it could come in better than expected if the underlying markets strengthen, especially in places like China? Thanks.

Francis Van Parys

executive
#74

All right. For the second half, we have fairly solid visibility into orders already scheduled that should ship during that period. Those provide a strong foundation for the acceleration in growth. On top of that, our pipeline looks quite healthy. We haven't built in any meaningful improvement in China or the Middle East, since those remain unknowns right now, and both hurt us in the first half. In fact, the pipeline gives us quite a bit of confidence about how the second half will play out. We also anticipate that a number of contracts in the Americas, which slipped from the first half into the second half, will come through. Altogether, that leaves us with fairly strong confidence as we head into 2026 for the second half.

Nicholas Keher

executive
#75

Yeah, and let me piggyback on that too. Looking at invoice ships or scheduled, our coverage is exactly the same as it was at this point a year ago, when we posted 24% growth for the full year. On a relative basis, that same level of coverage is there, and so is the confidence. As for how the second half kicked off, we've really only had July so far, and it matches the numbers we anticipated. There's plenty more work ahead, but as you'd expect, the summer months are always the quiet stretch. We've consistently noted that Q2 is seasonally — Q3, sorry — is always seasonally a touch softer than Q2 and Q4. Still, we already have that foundation from the coverage in hand today and the size of the pipeline, which keeps expanding. We also have substantial pipeline coverage in regions like the Americas. On the second question about research, we're assuming mid-single digit. Yes, pressures have shown up, particularly around National Institutes of Health. From a research growth rates standpoint, Europe remains quite healthy. Is there an opportunity to do better?

Nicholas Keher

executive
#76

That would presuppose the external environment has to get better. We haven't factored that in at this point. Our assumption is mid-single-digits, and that's what our plan is based on. If we're able to do better, we certainly will. Just in case that was more of a medium-term point or this year — because that single digit, yes, definitely for this year. Over the medium term, we believe it will be stronger, thanks to the focus on target applications. I think it also gives us a chance to talk about — hopefully people can see that greater than GBP 700 million, there is some prudence built into this regarding the haircuts we've taken. So we haven't assumed actually material improvements in the end market. We've assumed quite a significant headwind for China, actually, within that number as well, given the market dynamics we can't control. So, yeah, absolutely, it could be something that does better over the medium term, for sure.

Sam England

analyst
#77

Thanks a lot. That's great.

Operator

operator
#78

Thanks a lot, sir. The next question comes from Kane Slutzkin at Deutsche Bank. Go ahead, your line is open.

Kane Slutzkin

analyst
#79

Good morning, everyone. In the release, you noted that no new platform or commercial infrastructure is needed. So does that mean the current manufacturing and commercial footprint can handle revenue above that GBP 700 million without a significant CapEx step up? How should we view that capital intensity out to 2030? And maybe the last one is just any view on Roche's launch. Essentially, what's your assessment, or how has that evolved now that it's launched? Has that shifted the growth or pricing assumptions built into any of your medium-term targets? Thank you.

Francis Van Parys

executive
#80

Yeah, thanks for that question. Regarding commercial infrastructure and R&D, we believe the current level is pretty much right. Starting in 2028, we assume we'll keep investing in both at a rate suited to the growth we see ahead. That doesn't mean everything stays the same, though. To execute the strategy, we need to refocus our projects toward where growth exists and where ROI will come from. It also calls for refinements in our go-to-market structure, which will allow greater specialization to support customers in the segments we're targeting. In terms of just investment magnitude, we don't expect material change. On the manufacturing footprint, that's something we're working through. We're now working through operationalizing the strategy, as we said before. One element there is: what does our manufacturing footprint need to look like to support the volumes we foresee by 2030? That will likely mean some expansion at some point. More details to follow as we make those decisions. Those decisions are actually quite near term, because, as you know, you don't build a factory in a day.

Nicholas Keher

executive
#81

Also, regarding the CapEx through 2030, that figure would mainly relate to a manufacturing facility if that decision gets made — and obviously we’re examining it and will return to it. What I’d say is it won’t significantly distort the company’s profile. It would be distributed across a multi-year period. It won’t be — we can discuss offline — but what we’re focused on here is flow cell manufacturing, and we’re thinking carefully about whether to have a second facility, since even from a BCP standpoint we’ll want one by then, and we’ll consider territories. We’ll also consider funding for the manufacturing facility and where that could come from. We’ll pull all of that together and work through it over the next six months, and we’ll have more to say. On the Roche assessment, I mean, Francis does want to-

Francis Van Parys

executive
#82

Yeah. Commercially speaking, placements are happening. I've sat down with customers who are putting money into the platform. It's early days. Honestly, we see this as a neighboring area for us, and it doesn't come at the cost of where Oxford Nanopore is aiming our applications. As we laid out today, our focus is on high-value applications where our technology can deliver a meaningful difference. Those are inherently quite different from where we think the Accelrys platform will focus and is focusing. It remains a short read-focused platform that is pursuing the higher throughput opportunities, and that typically isn't where our strategy is focused, nor will it be going forward. So it may well be a platform that sits in an adjacent space to ours.

Kane Slutzkin

analyst
#83

Thanks. Apologies — since I'm here, I wanted to build on what Sam asked about research. Was that discussion about research in general? Specifically on the U.S. side, what's reflected in the figures, or expected for the rest of 2026 and into 2027, when it comes to U.S. academic or government funding?

Nicholas Keher

executive
#84

Looking at total research revenue, it's growing at a single-digit pace — low single digits, basically. I mean, on all of that, we've definitely still beaten what our peers are delivering. But there's a fair amount of mix in there between academic and government-funded work, and that segment has obviously been really tough. So across the board, we're seeing a wide mix. Still, for the U.S., the total research revenue figure sits in the single digits.

Kane Slutzkin

analyst
#85

You're saying that's growth in the low single digits?

Nicholas Keher

executive
#86

Yes.

Kane Slutzkin

analyst
#87

All right, that's great. Thank you, Nick.

Operator

operator
#88

Thanks. That was your question, sir. We're now going to move on to Miles Dixon, who's calling from Peel Hunt. Please go ahead.

Miles Dixon

analyst
#89

Nick, Francis, thanks for taking my questions — and apologies if these have come up already, since my line dropped. I'd like to ask about operating costs. Nick, that trajectory over three halves has really been impressive. I was wondering about the guidance. Although you've improved it today, the implication is that the second half could show a step-up in operating costs. Is that simply some additional headroom you're building in, or is there genuinely something that might mean a bit more cost in the second half? Does any of it tie to the GBP 20 million license fee deal announced today? Finally, a technical point — if I may ask about capitalized development spend, which is creeping up on R&D. How should we expect that to move going forward? What's the driver that's really changing that, or the classification to capitalize it rather than expense it? Thank you.

Nicholas Keher

executive
#90

Yeah. Great. Thank you. Thanks, Miles. For sure, operating costs are creating some prudence and headroom for the second half. That doesn't mean we won't possibly see some step-up in certain areas. As you saw today, the leadership team is being built out, and clearly, from a cost perspective, that's going to add to the bottom line. Nothing related to the cross licensing agreement with the global diagnostics company that we've talked about. So there's no cost to us tied to that. Yeah, building in a bit of prudence, but also just allowing for the fact that we may see some build-out in certain areas as well, before we think about that reallocation piece, kind of. On capitalized development spend, absolutely right. The things that have been growing here, it's more about the platform maturing. As products go from more research and then into development because they're becoming commercially available for customers, this is just the accounting rules essentially being applied to our R&D spend. Looking forward, the overall spend level is going to be broadly similar. There are a few pieces, though, that I don't want to hide away from, which is things like protein, where protein is predominantly like a research activity today, but we're getting close, and that will switch to being more development-led, potentially over 2027, and certainly over 2028.

Nicholas Keher

executive
#91

That part right there is the major item I can see emerging. Apart from that, the platform is essentially in place, and the total spend and the split are broadly correct. The only thing is, if I had to highlight something, I can see movement coming on the protein piece. Beyond that, it's simply a matter of applying the accounting rules. Basically, it comes down to the platform growing more mature. This isn't about building some entirely new process whose effectiveness we haven't established. What this is really about is refining processes that we already know work today and bringing in elements such as automation, and that kind of thing.

Miles Dixon

analyst
#92

Thanks, Nick.

Nicholas Keher

executive
#93

That's not a problem at all, Miles.

Francis Van Parys

executive
#94

I appreciate that.

Operator

operator
#95

Thanks. That brings us to the close of the question session. We'll now take a question from Julie Simmonds at Panmure Gordon. Julie, please go ahead. Your line is open. Thank you.

Julie Simmonds

analyst
#96

Thanks a lot. I have two questions, if I may. First, on the larger strategic side. Near term, biopharma appears to be the biggest growth area, and I'm simply wondering if that's due to where you stand with customers right now, or simply because adoption happens faster in biopharma than it does in the clinical space. Second, regarding consumables in the current business, I'm wondering how much of the slower consumable sales this year ties to the shift in business model toward the capital first side, and whether you have a sense of how long a capital sold instrument takes to reach the levels you would previously have expected — assuming you expect them to get there — or whether there's a significant change on that front. Thank you.

Francis Van Parys

executive
#97

Thanks for the question. I'll handle the first one, and then I'll let Nick respond to the second. Regarding the biopharma opportunity, you're right that adoption of the technology and validation happens more quickly there than on the clinical side. That isn't to say the validation cycle lacks rigor or is short. However, once a specific quality control process is in place for one molecule, replicating it across other molecules becomes simpler. The testing is repetitive, so once it's included in a filing with the FDA, for example, the technology is clearly established and used again and again. So adoption comes more as a step change, if you will. In clinical, that opportunity is a longer-term process, particularly as you move past laboratory-developed tests and into IVD. That represents a longer-term development opportunity. So we expect the bigger impact to come — even though it's significant for our growth in 2030, the bigger impact will still be ahead, and it will likely surpass the biopharma opportunity after 2030. I'll take the second question.

Nicholas Keher

executive
#98

Yeah, thanks. And that's a solid point too, Julie, about the consumables side. No question. So if someone went back to check how many flow cells, say, they committed to when they picked up a project pack, we mentioned this back then — maybe that wasn't the right figure, since an active user wouldn't necessarily go through that many in a typical year. So we ended up with this sort of bolus effect: they'd burn through the flow cells, then it would fall to a certain level, and from there it would climb again. So what we're seeing now isn't that peak-and-trough pattern ahead of growth. It's more just buying what they need in the moment. I think that's a really important piece, because we're going through that normalization event where people purchase what they need and buy alongside the device they're buying outright. So there's definitely that normalization element we're working through right now. How long does it take for a customer to buy a device and then get up and running?

Nicholas Keher

executive
#99

This is a metric the commercial team and I basically monitor constantly, since it matters enormously. Now, it varies by device, by customer, and by which type of contract we're considering. But honestly, our thinking should center on under three months, since there's a training component they undergo—depending on their device—plus installation, setup, confirming the bioinformatics and all of it functions as they expect, and after that comes the ramp-up stretch we also observe. So over the last 12+ months we have definitely witnessed this, examining active utilization per device, how long it took until they reached the normal level, how many devices are running below it, and what action we need to take. So the data is in our hands. Obviously we don't make that data public. Still, we're watching it, and we can tell that this ramp-up ought to occur going forward, especially at the consumable level. I mean, just to—sorry, really to drive the point home—on the larger P24 specifically, utilization growth has been consistently rising year-on-year.

Nicholas Keher

executive
#100

Since we’re now up against those bigger research programs—the GBP 8.3 million, NIHR, GEL 2.0, and PRECISE II—that’s only the first-half headwind. Most of that was consumables too. Even so, we’ve been putting out a lot of devices with new customers, and over the next 3 months+, they’re going to begin ramping up.

Julie Simmonds

analyst
#101

Great, thanks so much.

Operator

operator
#102

Thanks, Julie. We’ll take our next question from James Orsborne at Stifel. James, please go ahead.

James Orsborne

analyst
#103

Hi, Nick. Hi, Francis. Thanks for taking the questions, and just two, if I may. First, on the adjusted EBITDA margins for 2030, I think you said greater than 15%. Is there any reason this cannot be higher? I know your competitors, more established competitors, are close to the high 20s. What are the long and term expectations here? Is that high 20s possible for Oxford Nanopore versus the peers? Then second question is around the GBP 100 million cash trough. I think you mentioned this still stand. Is that inclusive of the licensing and royalties, or is that based on the pure organic previously? Maybe just how you view this in terms of you have mentioned selected M&A and how that kind of incorporates into your free cash flow breakeven target in 2028, and breakeven target in general. Thank you.

Francis Van Parys

executive
#104

Appreciate the question. I'll kick things off, and then Nick, you can pick it up from there. Regarding adjusted EBITDA, we've guided to 15% or more, so there could be room to do better than that. Worth noting as well: that figure doesn't factor in anything from royalties tied to the cross-licensing arrangement we mentioned earlier today, and it also leaves out any potential gains from other partnerships or business development deals we might pursue between now and 2030. So we see upside beyond that number. Peers sit in the 20s. Over the medium to long term, there's no reason we can't reach that level. We're fairly confident we can get there. For now, we're taking a conservative stance on what we're committing to for 2030. That commitment is 15% or more.

Nicholas Keher

executive
#105

Right, exactly. The only other point I'd make, just to add, is that it really hinges on where that revenue figure lands. So you're above GBP 700 million. Obviously, GBP 701 million is going to be greater than 15%, but if it's GBP 800 or GBP 900 million or GBP 1 billion, obviously the adjusted EBITDA margin overall is going to be higher. I think the key thing is that royalty figure will be additive on top, because it comes through at 100% gross margin with no costs underneath. On the GBP 100 million cash trough as well, yes. So even on the underlying basis, we're still going to go through that GBP 100 million. Obviously, it will now benefit from the royalties going on top. There will be more to update on this front, I think, at the end of the year in terms of allocation of capital, et cetera, and how that will look going forward. Selective M&A — I know Frans will add to this. As the capital allocation framework sets out, it's about innovation, internal innovation, and driving organic growth. The second piece is about partnerships and allocating capital there. The third piece is then about M&A.

Nicholas Keher

executive
#106

But over the short term—we're going to build out the plan in line with that type of workflow that you've observed. We'll return at the appropriate moment when further discussion is needed. We aren't going to do a deal. Sorry. It's supported by the balance sheet's strength. We won't do anything that removes our foundational balance sheet strength. So it could be somewhat later than 2028 before we begin considering the M&A pieces.

James Orsborne

analyst
#107

Great. All right, thanks a lot. That’s very clear.

Operator

operator
#108

Appreciate that, Mr. James. Since nobody else has anything to ask right now, I'll hand things back to your hosts in case they want to add anything or wrap up. Thanks.

Francis Van Parys

executive
#109

All right. If there are no more questions, I'd like to thank you for taking the time to be with us, for posing your questions, and for your interest in our update. I hope you found it both useful and insightful. We look forward to engaging further over the coming days and months, and we remain available to answer any additional questions and to share our views on the market. As we said regarding pillars two and three of our strategy, you should expect us to return at the full-year results, when we will share more detail on how we plan to operationalize that strategy. We're now going to get back to work. Thank you.

Nicholas Keher

executive
#110

Thanks a lot.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Oxford Nanopore Technologies plc transcript — plus 131,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Oxford Nanopore Technologies plc earnings transcripts and 131,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Oxford Nanopore Technologies plc or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.